Ofatumumab

Drugs

Volumn 70, Issue 8, 2010, Pages 1013-1019

  Sanford, Mark ^a   McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Chronic lymphocytic leukaemia; General; Ofatumumab; Research and development

Indexed keywords

ALEMTUZUMAB; ARZERRA; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN EXPRESSION; AREA UNDER THE CURVE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COUGHING; CYTOLYSIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRAFFIC; DYSPNEA; FATIGUE; HUMAN; INFECTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 77952628343     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11203850-000000000-00000     Document Type: Review

References (19)

1. Montserrat E, Moreno C. Chronic lymphocytic leukaemia: a short overview. Ann Oncol 2008 Sep; 19 Suppl. 7: vii320-5
2. Shanafelt TD, Call TG. Current approach to diagnosis and management of chronic lymphocytic leukemia. Mayo Clin Proc 2004 Mar; 79 (3): 388-398
3. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15; 111 (12): 5446-5456
4. Faderi S, Ferrajoli A, Frankfurt O, et al. Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy. Leukemia 2009; 23 (3): 457-466
5. Tsimberidou A-M, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 2009 Jul 1; 115: 2824-2836
6. Tam CS, O'Brien S, Lerner S, et al. The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphade-nopathy. Leuk Lymphoma 2007 Oct; 48 (10): 1931-1939
7. GlaxoSmithKline. Arzerra™: prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/ 125326lbl.pdf [Accessed 2010 Jan 25]
8. Genmab. GlaxoSmithKline receives conditional marketing authorization in the EU for Arzerra™ (ofatumumab) [media release]. 2010 Apr 19
9. Bleeker WK, Munk ME, Mackus WJ, et al. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008 Feb; 140 (3): 303-312
10. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological ac-tivity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006 Jul 1; 177 (1): 362-371
11. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009 Jul 1; 183 (1): 749-758
12. Beum PV, Lindorfer MA, Beurskens F, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol 2008 Jul 1; 181 (1): 822-832
13. Craigen JL, Mackus WJM, Engleberts P, et al. Ofatumu-mab, a human Mab targeting a membrane-proximal small-loop epitope on CD20, induces potent NK cell-mediated ADCC [abstract no. 1725]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
14. GlaxoSmithKline. Arzerra™ (ofatumumab) injection for intravenous use: FDA Oncological Drugs Advisory Committee briefing document [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4444b1- 02-GSK.pdf [Accessed 2010 Jan 26]
15. Osterborg A, Biilmann Ronn B, Jewell RC, et al. Correla-tion between serum ofatumumab concentrations, baseline patient characteristics and clinical outcomes in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL) treated with single-agent ofatumumab [abstract no. 3433]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-8; New Orleans (LA)
16. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as sin-gle-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28 (10): 1749-1755
17. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and effi-cacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008 Feb 1; 111 (3): 1094-1100
18. National Cancer Institute. Common terminology criteria [online]. Available from URL: http://ctep.cancer.gov/pro-tocolDevelopment/electronic- applications/docs/ctcaev3. pdf [Accessed 2010 Feb 3]
19. European Medicines Agency. Arzerra: summary of opinion (initial authorisation) [online]. Available from URL: http://www.emea.europa.eu/pdfs/ human/opinion/Arzerra- 214261en.pdf [Accessed 2010 Jan 25]